Merck, known outside the United States and Canada as MSD, today announced that the HPS2-THRIVE (Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events) study of TREDAPTIVE(extended-release niacin/laropiprant) did not meet its primary endpoint.
[More]
Dyslipidemia is defined as abnormal levels of blood lipids (fats) and cholesterol. The most common dyslipidaemias are high blood cholesterol (Total Cholesterol) and triglyceride levels, high levels of low-density lipoprotein (LDL) cholesterol (‘bad’ cholesterol) and low levels of high-density lipoprotein (HDL) cholesterol (‘good’ cholesterol).
[More]
A novel approach to identifying potential anticancer drug combinations revealed that pairing cholesterol-reducing drugs called statins with cyclin-dependent kinase inhibitors might provide an effective approach to treating intractable melanomas driven by mutations in the NRAS and KRAS gene.
[More]
Researchers from The University of Texas MD Anderson Cancer Center found statins, the commonly used drug to lower cholesterol, improved progression-free survival in patients with inflammatory breast cancer (IBC).
[More]
Researchers from The University of Texas MD Anderson Cancer Center found statins, the commonly used drug to lower cholesterol, improved progression-free survival in patients with inflammatory breast cancer (IBC).
[More]
Exposure to traffic-related air pollutants is associated with a rapid increase in systemic inflammation in patients with diabetes, report Indian researchers.
[More]
Telephoning and writing to individuals who have not filled their new prescription for statin medication significantly improves rates of prescription uptake, show US study results.
[More]
Taking statins or being even modestly physically fit markedly improves survival in people with dyslipidaemia (abnormal levels of harmful blood fats/cholesterol), according to new research published Online First in The Lancet. But combining statin treatment with better fitness may do more to ward off death than either intervention alone.
[More]
Literally hundreds of clinical trials, including some that have gained widespread attention, have been done on the possible benefits of omega-3 fatty acids for the prevention of heart disease - producing conflicting results, varied claims, and frustrated consumers unsure what to believe.
[More]
Patients newly prescribed a cholesterol-lowering medication were more likely to pick it up from the pharmacy if they received automated phone and mail reminders, according to a study published in the Archives of Internal Medicine today.
[More]
People are much more likely to take heart medicines if they're combined in one pill, according to a late-breaking clinical trial presented at the American Heart Association's Scientific Sessions 2012.
[More]
Amgen today announced that results from the LAPLACE-TIMI 57 and MENDEL Phase 2 studies evaluating AMG 145 in hypercholesterolemic patients with or without statins, respectively, showed that treatment with AMG 145 resulted in a statistically significant reduction in low-density lipoprotein (LDL) cholesterol.
[More]
For many people with high cholesterol, statins serve as the first line of treatment. However, some patients are unable to effectively reduce their low-density lipoprotein cholesterol (LDL cholesterol) or "bad cholesterol" levels with statins, the most commonly used medication to treat high cholesterol, due to their bodies' inability to tolerate or sufficiently respond to the medicine.
[More]
Amgen will present data from four Phase 2 trials of AMG 145, an investigational fully human monoclonal antibody directed against PCSK9, a protein that reduces the liver's ability to remove low density lipoprotein cholesterol, or "bad" cholesterol from the blood, at the upcoming American Heart Association Scientific Sessions 2012.
[More]
In the United States, the cost paid for statins (drugs to lower cholesterol) in people under the age of 65 who have private insurance continues to exceed comparable costs paid by the government in the United Kingdom by more than three fold.
[More]
Arterial stiffening has long been considered a major risk factor for cardiovascular disease. Keeping arteries soft and supple might reduce disease risk, but the mechanisms of how arteries stave off hardening has remained elusive.
[More]
High blood cholesterol, a serious hereditary disease, is far more common than previously recognised and not treated sufficiently.
[More]
The quinolinone derivative cilostazol may be associated with reduced restenosis, reocclusion, and clinically driven target lesion revascularization 3 months after infrapopliteal angioplasty, researchers say.
[More]
Statins, a cholesterol lowering drug may lower the risk of esophageal cancer, especially in patients with Barrett's esophagus, Mayo Clinic researchers report in a study being presented at the American College of Gastroenterology annual meeting.
[More]
Patients who have undergone resection for non-small cell lung cancer (NSCLC) may improve their overall survival and reduce the risk of recurrence by taking statins.
[More]